Inhaled Biologicals for the Treatment of Cystic Fibrosis.

ABSTRACT:

Background

Cystic Fibrosis (CF), one of the most frequent genetic diseases, is characterized by the production of viscous mucus in several organs. In the lungs, mucus clogs the airways and traps bacteria, leading to recurrent/resistant infections and lung damage. For cystic fibrosis patients, respiratory failure is still lethal in early adulthood since available treatments display incomplete efficacy.

Objective

The objective of this review is to extend the current knowledge in the field of available treatments for cystic fibrosis. A special focus has been given to inhaled peptide-based drugs.

Methods

The current review is based on recent and/or relevant literature and patents already available in various scientific databases, which include PubMed, PubMed Central, Pate

SUBMITTER: Sala V 

PROVIDER: S-EPMC6751348 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature